BMT, Gamida Cell Ltd, hematologic malignancies, Omidubicel
Omidubicel is approved by USFDA to reduce time to neutrophil recovery and infection in patients with hematologic malignancies
May 2023: Omidubicel-onlv (Omisirge, Gamida Cell Ltd.) was approved by the Food and Drug Administration for use in adult and paediatric patients (12 years of age and older) with hematologic malignancies who are scheduled to recei..